Formulary management of colony-stimulating factors

American Journal of Health-System Pharmacy

Volumn 59, Issue SUPPL. 2, 2002, Pages

  Whalen, Cathy R ^a   Watson, Tamara L ^a   Baize, Timothy ^a   Ball, Amy ^a  

^a UNIVERSITY OF LOUISVILLE HOSPITAL   (United States)

Author keywords

Antineoplastic agents; Costs; Drug comparisons; Equivalency, therapeutic; Filgrastim; Formularies; Neutropenia; Pharmaceutical services; Pharmacy, institutional, hospital; Sargramostim; Substitution; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CELL COUNT; CHRONIC LYMPHATIC LEUKEMIA; CONFERENCE PAPER; COST CONTROL; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEUTROPENIA; NEUTROPHIL; OUTCOMES RESEARCH; PHARMACY; PHARMACY AND THERAPEUTICS COMMITTEE; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0036534045     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.suppl_2.s21     Document Type: Conference Paper

References (12)

1. ASHP guidelines on formulary system management
2. ACCP position statement: Guidelines for therapeutic interchange
3. AMA policy on drug formularies and therapeutic interchange in inpatient and ambulatory patient care settings
4. Outcomes of an amplodipine-to-felodipine therapeutic interchange program
5. Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease
6. Impact of therapeutic interchange from pravastatin to lovastatin in a Veterans Affairs Medical Center
7. Therapeutic interchange of fluoroquinolones at a medical center
8. Proton pump inhibitor therapy: Preliminary results of a therapeutic inter change program
9. Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy
10. Therapeutic-interchange program for oral histamine H2-receptor antagonists
11. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
12. The expanding world of colony-stimulating factors